A股異動 | 博騰股份(300363.SZ)漲6% 擬收購宇陽藥業70%股權
格隆匯8月19日丨博騰股份(300363.SZ)股價高位震盪,現報91.75元,漲幅6%,最新總市值499.22億。公司18日公吿稱,擬1.71億元收購宇陽藥業70%股權,後者主營業務為醫藥中間體的研發、製造與銷售,主要產品為心腦血管類藥物、降血脂類藥物、抗外周神經痛及抑鬱藥物等醫藥中間體。本次交易完成後,公司將擁有3個化學原料藥CDMO生產基地,產能將進一步擴大至2,000m³。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.